Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.24.3
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Consolidated Statements of Operations and Comprehensive Loss    
Revenues $ 225,000 $ 0
Operating expenses:    
Research and development 5,185,000 10,327,000
General and administrative 11,674,000 19,016,000
Total operating expenses 16,859,000 29,343,000
Operating loss (16,634,000) (29,343,000)
Other income (expense):    
Interest expense (172,000) (83,000)
Interest income 363,000 213,000
Loss on sales of debt securities   (98,000)
Gain on sale of intellectual property 1,000,000  
Total other income 1,191,000 32,000
Net loss from continuing operations (15,443,000) (29,311,000)
Loss from discontinued operations (9,464,000) (35,699,000)
Net loss (24,907,000) (65,010,000)
Comprehensive loss:    
Consolidated net loss (24,907,000) (65,010,000)
Other comprehensive loss - unrealized loss on debt securities   180,000
Other comprehensive income - foreign currency adjustment   33,000
Comprehensive loss $ (24,907,000) $ (64,797,000)
Per share amount - continuing operations (Basic) $ (4.03) $ (47.88)
Per share amount - continuing operations (Diluted) (4.03) (47.88)
Per share amount - discontinued operations (Basic) (2.47) (58.31)
Per share amount - discontinued operations (Diluted) (2.47) (58.31)
Loss per common share attributable to iBio, Inc. stockholders - basic - total (6.50) (106.19)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total $ (6.50) $ (106.19)
Weighted-average common shares outstanding (Basic) 3,831 612
Weighted-average common shares outstanding (Diluted) 3,831 612